Multi-center, Randomized, Double-blind Efficacy and Safety of CD0271 0.3%/CD1579 2.5 % Topical Gel in Acne Vulgaris
Status:
Completed
Trial end date:
2014-03-01
Target enrollment:
Participant gender:
Summary
The study hypothesis are based on the assumption that :
- CD0271 0.3%/CD1579 2.5% Gel provides superior clinical efficacy compared with Topical
Gel Vehicle in the overall population and in the subgroup of severe Subjects
- CD0271 0.3%/CD1579 2.5% Gel applied once daily for up to 12 weeks has an acceptable
safety and tolerability profile